JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schenk, S.
Right arrow Articles by Greinacher, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schenk, S.
Right arrow Articles by Greinacher, A.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Congestive Heart Failure
Right arrow Mechanical Circulatory Assistance

J Thorac Cardiovasc Surg 2006;131:1373-1381
© 2006 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support

Soren Schenk, MD a , Aly El-Banayosy, MD a , * , Wolfgang Prohaska, MD b , Latif Arusoglu, MD a , Michiel Morshuis, MD a , Wilhelm Koester-Eiserfunke, PhD b , Lukasz Kizner, MD a , Edward Murray, MD a , Petra Eichler, PhD c , Reiner Koerfer, MD a , Andreas Greinacher, MD c

a Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
b Laboratory and Transfusion Medicine, Heart Center North Rhine-Westphalia, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
c Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany.

Received for publication May 2, 2005; revisions received December 18, 2005; accepted for publication January 10, 2006.

* Address for reprints: Aly El-Banayosy, MD, Heart Center NRW, Georgstrasse 11, Bad Oeynhausen, Germany, 32545. (Email: abanayosy{at}hdz-nrw.de).

OBJECTIVES: Patients receiving mechanical circulatory support are at risk for the development of heparin-induced thrombocytopenia due to the prolonged postoperative use of heparin. We evaluated their antibody status and outcome.

METHODS: Between 2003 and 2004, 115 patients received mechanical circulatory support for more than 5 days. Blood samples from postoperative day 7 were retrospectively analyzed for anti–platelet factor 4/heparin antibodies and heparin-induced platelet activation.

RESULTS: Overall, 12 (10.6%) patients had heparin-induced thrombocytopenia as defined by in vitro platelet activation, 28 (24.8%) had nonactivating antibodies, and 73 (64.6%) were classified as negative for antibodies. Patients positive for heparin-induced thrombocytopenia had the highest levels of anti–platelet factor 4/heparin immunoglobulin G antibodies. Freedom from thromboembolism was 33%, 33%, and 16% at 1, 3, and 6 months for positive patients, 77%, 68%, and 55% for negative patients (P < .001), and 70%, 53%, and 53% for patients with nonactivating antibodies (P = .068), respectively. The relative risk for thromboembolism in antibody positive patients peaked in the first month of support (odds ratio 7.46, P = .002). Independent risk factors for thromboembolic events included higher anti–platelet factor 4/heparin antibody titers, female gender, and higher fibrinogen levels.

CONCLUSION: Heparin-induced thrombocytopenia was more prevalent in patients receiving mechanical circulatory support than in other cardiac patients. Frequent antibody screening is recommended due to the increased risk of thromboembolism. Heparin alternatives should be subjected to clinical trials in these high-risk patients.

Abbreviations and Acronyms aPTT = activated partial thromboplastin time; CAA = column agglutination assay; EIA = enzyme immunoassay; HGW = Hansestadt Greifswald; HIPA = heparin-induced platelet activation assay; HIPA+&id/ IgG+ = heparin-induced platelet activation assay positive or indeterminate with IgG titers of OD > 1.0; HIPA–/IgG,A,M+ = heparin-induced thrombocytopenia platelet activation assay negative and IgG, IgA, and IgM antibodies; HIT = heparin-induced thrombocytopenia; Ig = immunoglobulin; INR = international normalized ratio; MCS = mechanical circulatory support; OD = optical density; PF4 = platelet factor 4; POD = postoperative day; TIA = transient ischemic attack




This article has been cited by other articles:


Home page
 ChestHome page
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 340S - 380S.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. J. Weiss, L. W. Miller, and F. D. Pagani
Continuous-Flow Ventricular Assist Device
N. Engl. J. Med., November 29, 2007; 357(22): 2305 - 2306.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Koster
Reply
Ann. Thorac. Surg., October 1, 2007; 84(4): 1423 - 1424.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. N. Schroder, M. A. Daneshmand, N. R. Villamizar, R. P. Petersen, L. J. Blue, I. J. Welsby, A. J. Lodge, T. L. Ortel, J. G. Rogers, and C. A. Milano
Heparin-Induced Thrombocytopenia in Left Ventricular Assist Device Bridge-to-Transplant Patients
Ann. Thorac. Surg., September 1, 2007; 84(3): 841 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. E. Warkentin and M. A. Crowther
When is HIT Really HIT?
Ann. Thorac. Surg., January 1, 2007; 83(1): 21 - 23.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.